Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/26/2005CN1688197A Gene therapy for critical limb ischemia with wild type or mutant eNOS
10/26/2005CN1686562A Composition of transiron protein and biological reducing agent and its preparation method
10/26/2005CN1686537A Acupuncture point injection mixture for treating mastopathy proliferation, its preparation method and application
10/26/2005CN1686536A Blood nourishing body building composition and its production method
10/26/2005CN1686535A Preparation method of medicinal composition containing glutathione peroxidase
10/26/2005CN1686534A Medicinal composition using anterior pituitary adrenal cortical extract as main component, and its preparation method and use
10/26/2005CN1686533A Cyclosporia A microemulsion for eye and its preparation method
10/26/2005CN1686532A Conjugated linoleic acid contained nutrient for body weight reducing people
10/26/2005CN1224708C i (Neisseria meningitidis) antigens
10/26/2005CN1224707C Intracellular isoform of the interleukin-1 receptor antagonist
10/26/2005CN1224630C Targetted polypeptide for specificity of liver cancer blood vessel
10/26/2005CN1224629C Phrazinone protease inhibitors
10/26/2005CN1224627C Modified factor VIII
10/26/2005CN1224421C Novel specific mechanism for inhibiting adherence of platelets to collagen
10/26/2005CN1224420C Agent for treating visual cell function disorder
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224418C Biological preparation containing marine active substance and use thereof
10/26/2005CN1224391C Endoparasiticidal combination
10/26/2005CN1224385C Medicament contg. platinum complex compounds and use thereof
10/25/2005US6958388 Amino acid sequence for treating lung diseases, such as idiopathic pulmonary fibrosis
10/25/2005US6958387 Human serpin polypeptides
10/25/2005US6958386 MUM-1 protein expressed by multiple myeloma-related gene
10/25/2005US6958383 Streptogramin derivatives, preparation method and compositions containing same
10/25/2005US6958361 Drugs, vaccines
10/25/2005US6958323 Nervous system disorders; cardiovascular disorders; gastrointestinal disorders
10/25/2005US6958321 Isolation, characterization, cloning and use of a mushroom lectin
10/25/2005US6958320 Sel-12 related methods
10/25/2005US6958319 Stability and longer shelf life; bortezomib N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
10/25/2005US6958318 Recombinant bacterial cells for delivery of PNP to tumor cells
10/25/2005US6958241 Liposomes with outer surfaces having an affinity moiety that binds to a biological therapy target surface, and a hydrophilic polymer coating reversibly conjugated to said moiety; e.g. polymyxin B conjugate liposome for septic shock
10/25/2005US6958240 Inhibition of major groove DNA binding proteins by modified polyamides
10/25/2005US6958238 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
10/25/2005US6958224 Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
10/25/2005US6958220 Inhibitors of proteasomal activity for stimulating hair growth
10/25/2005US6958212 coupling of a pharmaceutically active compound to a polymer using a conjugate addition reaction, and the cross-linking of the polymer to form a biomaterial, in some embodiments using conjugate addition reactions; controlled release of drug
10/25/2005US6958160 liposomes include diacylglycerol-PEG compounds; melting point below about 40 degrees C, and acyl chains greater than or equal to 14 carbons in length; use in drug delivery, diagnostics, cosmetics, cosmeceuticals and nutraceuticals
10/25/2005US6958153 topical formulation of azithromycin / clarithromycin macrocyclic lactone antibiotic or Tacrolimus/ Sirolimus immunosuppressive macrolide and permeation modulator; minimizes systemic exposure treating at site reduced side effects; scalp conditions
10/25/2005US6958151 Miniprotein ligands and other polypeptides and methods for making and using same
10/25/2005US6958150 Supplying collagenase, protease to tissue
10/25/2005US6958149 Repair of larynx, trachea, and other fibrocartilaginous tissues
10/25/2005US6958148 microparticle comprising active agent and polymer having transglutaminase substrate reactive groups, wherein reactive groups are surface available, and polymer comprises amino acids having at least three contiguous linked glutamines; drug delivery
10/25/2005US6958147 Use of VEGF-C to prevent restenosis
10/25/2005US6958142 Nasal spray formulation and method
10/25/2005CA2229045C Use of muteins of wild-type cytokines as immunogens
10/25/2005CA2084301C Heparin derivatives and process for the preparation thereof
10/21/2005CA2504582A1 Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer
10/21/2005CA2504401A1 Drug delivery systems for the prevention of neointimal hyperlasia
10/20/2005WO2005098449A2 Hausp-mdm2 interaction and uses thereof
10/20/2005WO2005098435A2 Peptides and peptidomimetics binding to cd23
10/20/2005WO2005098427A2 Method, composition and device for treating starch related diseases
10/20/2005WO2005097998A2 Il-18 specific polypeptides and therapeutic uses thereof
10/20/2005WO2005097994A1 Digoxigenin-binding muteins of the bilin-binding protein of pieris brassicae
10/20/2005WO2005097988A1 Bone marrow-relevant cell participating the maintenance and/or repair of tissue
10/20/2005WO2005097978A1 Modulation of granulosa cell proliferation and differentiation
10/20/2005WO2005097828A2 Peptides of cav2.2 that inhibit pain
10/20/2005WO2005097822A1 Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
10/20/2005WO2005097814A2 Composition and method for inhibiting platelet aggregation
10/20/2005WO2005097262A1 A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern
10/20/2005WO2005097261A1 Method of reducing c-reactive protein using growth hormone secretagogues
10/20/2005WO2005097204A1 Preventives/remedies for cancer
10/20/2005WO2005097200A2 Tetanus toxin fusion protein for visualization of active synapses
10/20/2005WO2005097195A2 Methods of reducing aggregation of il-1ra
10/20/2005WO2005097189A1 Carcinoma cell-specific apoptosis inducing agent targeting gene relevant to chromosome stabilization
10/20/2005WO2005097179A2 Stabilised tat antigen and the use thereof for anti-hiv vaccination
10/20/2005WO2005097178A1 Pressure sore treatment
10/20/2005WO2005097177A1 Use of collagenase to facilitate guide wire crossing in total arterial occlusions
10/20/2005WO2005097176A2 Modulating oxalate transport
10/20/2005WO2005097175A2 Human glp-1 mimetibodies, compositions, methods and uses
10/20/2005WO2005097174A2 Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
10/20/2005WO2005097172A2 Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
10/20/2005WO2005097171A1 Antiobesity drug
10/20/2005WO2005097170A1 Angiogenesis promoter and angiogenic therapy
10/20/2005WO2005097169A2 Novel immunotherapy
10/20/2005WO2005097168A2 Synthetic chemokines, methods of manufacture, and uses
10/20/2005WO2005097167A1 Combination dosing regimen for erythropoietin
10/20/2005WO2005097166A1 Remedy for diabetic neuropathy comprising gelatin gel as carrier
10/20/2005WO2005097165A2 Il-28 and il-29 cysteine mutants for treating viral infection
10/20/2005WO2005097164A2 Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
10/20/2005WO2005097163A1 Oligopeptides for reducing elevated blood urea concentration
10/20/2005WO2005097162A2 Steroid sparing agents and their use
10/20/2005WO2005097161A2 Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury
10/20/2005WO2005097160A2 Modulation of nkg2d
10/20/2005WO2005097159A1 Ophthalmic preparation containing glycoprotein
10/20/2005WO2005097158A1 Amphipathic glycopeptides
10/20/2005WO2005097157A1 Ophthalmic preparation containing glycomacropeptide
10/20/2005WO2005097156A1 Remedy for neurodegenerative diseases
10/20/2005WO2005097155A1 Neurite elongation inducing agent
10/20/2005WO2005097154A2 Neurotransmitter mixture which promotes the healing of wounds
10/20/2005WO2005097151A1 Antioxidant composition and products containing the same
10/20/2005WO2005097147A1 Restenosis therapy using mesenchymal stem cells
10/20/2005WO2005097146A2 Dairy components effective for fat loss
10/20/2005WO2005097116A1 Composition comprising a jnk inhibitor and cyclosporin
10/20/2005WO2005097088A2 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
10/20/2005WO2005097065A1 Composition comprising colony stimulating factor for treatment of a localised bacterial infection and bacterial related disease
10/20/2005WO2005097061A1 Encapsulated peptide copper complexes and compositions and methods related thereto
10/20/2005WO2005097060A1 Use of peptides as an antioxidant agent for the preparation of a cosmetic and/or pharmaceutical composition
10/20/2005WO2005096847A1 Method of preparing a food ingredient and food product having angiotensin-i-converting enzyme inhibiting properties and products thus obtained
10/20/2005WO2005085236A3 Caspase inhibitors and uses thereof
10/20/2005WO2005078077A3 Acid alpha-glucosidase and fragments thereof
10/20/2005WO2005076827A3 Fbsa compositions for use in promoting fibrinogen aggregation and potentiating fibrin polymerization
1 ... 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 ... 3163